Register Login
Register to leave comments
  • News bot May 5, 2026, 8:17 p.m.

    📋 PROTAGONIST THERAPEUTICS, INC (PTGX) - Financial Results

    Filing Date: 2026-05-05

    Accepted: 2026-05-05 16:08:27

    Event Type: Financial Results

    Event Details:

    PROTAGONIST THERAPEUTICS, INC (PTGX) Reports the reporting period Financial Results PROTAGONIST THERAPEUTICS, INC (PTGX) announced its financial results for the period ending the reporting period. Key Financial Highlights:
    • Revenue: 6282
    • Net Income: 70492618
    • EPS: Not disclosed
    • Cash and equivalents: 620334
      • week primary analysis and 52
      • week results from the Phase 3 global randomized VERIFY study, as well as four
      • year efficacy and safety data from the Phase 2 REVIVE study and long
        • anticipated by year-end; PN-477sc and PN-477o (sc and oral triple GLP/GIP/GICG agonist) Phase 1 initiation expected in mid-2026
        • anticipated in mid-2026
        • expected in mid-2026

    📊 Key Financial Metrics (Year-over-Year Comparison):

    Metric 2026 2025 Change ($) Change (%)
    Operating Expense Loss From Operations 3.65K 19.31K $-15.66K -81.11%
    Operating Expense Interest Income 5.88K 7.57K $-1.70K -22.41%
    Operating Expense Other Income Net 53.00 82.00 $-29.00 -35.37%
    Cash and Marketable Securities 620.33K 646.00K $-25.67K -3.97%
    Revenue 56.37K 28.32K $28.05K +99.03%
    Loss from Operations 3.65K 19.31K $-15.66K -81.11%
    Interest Income 5.88K 7.57K $-1.70K -22.41%
    Other Income, Net 53.00 82.00 $-29.00 -35.37%

    💼 Business Developments:

    • Partnership
    • Acquisition: Not available
    • Licensing: Not available
    • Regulatory Approval
    • Executive Changes: Not available

    Structured Data:

    • Company Name: PROTAGONIST THERAPEUTICS, INC
    • Ticker Symbol: PTGX

Search

News categories